
    
      This is an open-label randomized pilot research study to determine if the study drug,
      pembrolizumab, is safe to use in combination with a chemotherapy drug called paclitaxel. This
      study will have the following two regimens: Cohort A) phased regimen of pembrolizumab in
      which paclitaxel is followed by paclitaxel plus pembrolizumab and Cohort B) concurrent
      regimen of paclitaxel plus pembrolizumab. A total of 40 evaluable subjects will be enrolled
      over an enrollment period of 18-24 months. The study is planned to enroll approximately 20
      evaluable subjects in each treatment cohort.
    
  